Stay updated with breaking news from Efficacy With. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs TNF inhibitors, as well as their efficacy in patients with different levels of risk.
California, N.Y. to Open New Stadium Vaccine Sites: Virus Update Bloomberg 2/3/2021 Bloomberg News © Bloomberg People wearing protective masks wait in line to receive a dose of the Moderna Covid-19 vaccine at a walk up vaccination site in San Francisco, California, U.S., on Wednesday, Feb. 3, 2021. (Bloomberg) -- AstraZeneca Plc and the University of Oxford have started looking at how to re-engineer their coronavirus vaccine to defeat new mutations, saying a tweaked injection could be ready by autumn. GlaxoSmithKline Plc agreed to work with CureVac NV to help boost produc...
California, N.Y. to Open New Stadium Vaccine Sites: Virus Update Bloomberg 3/02/2021 Bloomberg News © Bloomberg People wearing protective masks wait in line to receive a dose of the Moderna Covid-19 vaccine at a walk up vaccination site in San Francisco, California, U.S., on Wednesday, Feb. 3, 2021. (Bloomberg) -- AstraZeneca Plc and the University of Oxford have started looking at how to re-engineer their coronavirus vaccine to defeat new mutations, saying a tweaked injection could be ready by autumn. GlaxoSmithKline Plc agreed to work with CureVac NV to help boost produ...
California, N.Y. to Open New Stadium Vaccine Sites: Virus Update Bloomberg 3/02/2021 Bloomberg News © Bloomberg People wearing protective masks wait in line to receive a dose of the Moderna Covid-19 vaccine at a walk up vaccination site in San Francisco, California, U.S., on Wednesday, Feb. 3, 2021. (Bloomberg) -- AstraZeneca Plc and the University of Oxford have started looking at how to re-engineer their coronavirus vaccine to defeat new mutations, saying a tweaked injection could be ready by autumn. GlaxoSmithKline Plc agreed to work with CureVac NV to help boost produ...